The overwhelming number of genetic alterations identified through cancer genome sequencing requires complementary approaches to interpret their significance and interactions. Here we developed a novel whole-body insertional mutagenesis screen in mice, which was designed for the discovery of Pten-cooperating tumor suppressors. Toward this aim, we coupled mobilization of a single-copy inactivating Sleeping Beauty transposon to Pten disruption within the same genome. The analysis of 278 transposition-induced prostate, breast and skin tumors detected tissue-specific and shared data sets of known and candidate genes involved in cancer. We validated ZBTB20, CELF2, PARD3, AKAP13 and WAC, which were identified by our screens in multiple cancer types, as new tumor suppressor genes in prostate cancer. We demonstrated their synergy with PTEN in preventing invasion in vitro and confirmed their clinical relevance. Further characterization of Wac in vivo showed obligate haploinsufficiency for this gene (which encodes an autophagy-regulating factor) in a Pten-deficient context. Our study identified complex PTEN-cooperating tumor suppressor networks in different cancer types, with potential clinical implications.
Although the sequencing of genomes from cancer cells has identified multiple genetic modifications underlying the carcinogenic process 1 , its ability to pinpoint players that are altered by nongenetic mechanisms is limited, and discerning between driver and passenger alterations still represents a major challenge. Moreover, such a strategy is not designed to elucidate cooperation between multiple driver genes. Indeed, some genes that were previously thought to be passengers are now believed to cooperate with other cancer-related genes and have thus become drivers 2 .
Insertional mutagenesis in mice is a valuable method for genomewide functional studies. Transposon-based somatic screens have identified new genes that are involved in the pathogenesis of different cancer types. Transposon mobilization in mice with known cancerpredisposing mutations has also uncovered synergistic mechanisms between networks that drive cancer progression [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Here we have enhanced the capabilities of transposon-based insertional mutagenesis to identify cooperating cancer driver events, by developing a system that allows both disruption of a known targeted gene and single-copy transposon mobilization to occur simultaneously in the same cell. Using this strategy we performed a mutagenesis screen in mice that was aimed at identifying loss-of-function alterations that cooperate with the inactivation of Pten, a tumor suppressor gene commonly deleted or mutated in cancer. In parallel, and for comparison with a more conventional setting, we generated another cohort of mice that harbor an additional concatemer of inactivating transposons.
Mobilization of a single transposon was sufficient to cause cancer in cooperation with the loss of Pten. The analysis of prostate, breast and skin tumors from these mice allowed for the identification of large numbers of Pten-cooperating candidate tumor suppressor genes. We focused on the prostate tumors and confirmed the functional and clinical relevance of five of these candidate genes (ZBTB20, CELF2, PARD3, AKAP13 and WAC) in cancer progression. Finally, in vivo validation in a prostate-specific Pten-deficient background showed that Wac, which encodes an autophagy regulator, is a novel obligate haploinsufficient tumor suppressor gene.
A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes and 291, respectively; skin, 287 and 665, respectively) ( Table 1 and Supplementary Tables 1-7) .
We observed 717 CIS that were specific to prostate tumors, 191 that were specific to breast tumors and 329 that were specific to skin tumors, whereas 101 CIS were common to all three tumor types. Of these, seven CIS were present in all of the lists (six in total) that we generated from the prostate, breast and skin tumors from the PSB and PISB mice, which included well-known Pten-cooperating genes (Nf1, Cul3 and Tnrc6b) and candidate tumor suppressor genes (Kansl1, Arih1, Dyrk1a and Chd2) ( Fig. 1f and Supplementary Table 8 ) 12, [20] [21] [22] . In summary, these genome-wide screens identified comprehensive sets of tumor suppressor genes that cooperate with Pten in a global or tissue-specific manner.
Transposition model mimics human prostate tumorigenesis
We focused on prostate cancer because of its high incidence in humans and in our mice, as well as the central role of PTEN in its pathogenesis. Pten +/− mice develop non-invasive prostate tumors with incomplete penetrance 23 , whereas complete tumor penetrance is observed after prostate-specific Pten inactivation 24 . The presence of concomitant genetic alterations in Pten +/− mice has also been shown to trigger prostate cancer progression [25] [26] [27] [28] [29] [30] . We hypothesized that the combination of the Pten SBm2 allele and expression of the SB transposase in PSB and PISB mice would facilitate the coupled inactivation of Pten and cooperating tumor suppressors. Moreover, the Blm deficiency should favor LOH of both the inactivated Pten allele and the transposontargeted loci, accelerating tumor formation and progression.
In agreement with these predictions, all male PSB (n = 38) and PISB (n = 49) mice showed prostate gland enlargement, which, in a high proportion (50% and 72%, respectively), progressed to invasive adenocarcinoma ( Fig. 1c) . Similarly to that seen in human prostate cancer, progression was accompanied by a decrease in Pten protein levels and a correlative increase in the proportion of actively proliferating (Ki67-positive) cells. Moreover, the contiguity of p63 staining, which is characteristic of normal epithelium and of prostate intraepithelial neoplasias (PIN), was lost in invasive adenocarcinomas ( Fig. 2a,b ). In addition, Pten LOH was detected in 9/9 analyzed tumors ( Fig. 2c) . These data indicate that prostate tumorigenesis in our model mirrors the progression of human prostate cancer, confirming suitability of this mouse model for the molecular characterization of this malignancy.
Prostate CIS are enriched in human genes involved in cancer
Notably, 70% of the prostate CIS genes found in PSB mice overlap with those found in PISB mice (P < 2.2 × 10 −16 ; Fisher's exact test) ( Fig. 2d and Supplementary Table 7 ), indicating that the same signaling pathways support prostate cancer development in both cohorts (significant overlaps were also observed in breast (P = 3.6 × 10 −16 ) and skin tumors (P < 2.2 × 10 −16 ) by Fisher's exact test; Supplementary  Fig. 3a,d and Supplementary Table 7 ). To explore the biological and clinical relevance of the genes identified in the prostate tumors, we determined their enrichment in genes that are known to be involved in human cancer. CIS genes with human homologs (hCIS) in tumors from PSB (n = 160 PSB hCIS) and PISB (n = 1,047 PISB hCIS) mice, as well as those shared between both groups (hereafter referred to as 'PSB∩PISB hCIS'; n = 115 PSB∩PISB hCIS) were analyzed independently. PSB, PISB and PSB∩PISB hCIS were significantly enriched in known and candidate genes involved in cancer (hereafter referred to as cancer genes) that are listed in the Cancer Gene Census (CGC) database (PSB, P = 5.50 × 10 −16 ; PISB, P < 2.2 × 10 −16 ; PSB∩PISB, P = 1.22 × 10 −14 ; by Fisher's exact test) and in the Network of A r t i c l e s Cancer Genes (NCG) 31 (PSB, P = 0.005377; PISB, P = 4.27 × 10 −7 ; PSB∩PISB, P = 0.003752; by Fisher's exact test), respectively ( Supplementary Fig. 4a,b and Supplementary Tables 9 and 10). This highlights the potential of combining human cancer sequencing with transposon-based screening for prioritizing and cross-validating candidate cancer genes.
We next asked whether hCIS were enriched in human prostate cancer genes. Genomic rearrangements and copy-number variations represent a major source of DNA alteration in prostate cancers. Given the exclusive inactivating capacity of our transposons, we compared the list of hCIS to genes that are recurrently deleted in human prostate cancer. The analysis of 336 primary prostate tumors from The Cancer Genome Atlas (TCGA) showed that a significant proportion of PSB, PISB and PSB∩PISB hCIS genes were homozygously deleted in this sample set (P = 0.01945, P = 1.82 × 10 −6 and P = 0.01042, respectively; by Fisher's exact test) ( Supplementary Fig. 4c Hyp.
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Hyp. Figure 1 A Sleeping Beauty-dependent inactivatable Pten allele for coupled whole-body mutagenesis and tumor suppressor discovery in mice. (a,b) Transposon-bearing mice used in this study. (a) Single-copy transposon-bearing (Pten SBm2/+ ; Rosa26 SB11/+ ; Blm m3/m3 -referred to as PSB) mice harbor the Pten SBm2 allele, in which Pten exon 5 is flanked by two Sleeping Beauty TRs. This converts the whole cassette into an inactivating transposon that can be mobilized and reintegrated in the genome by the SB transposase, while concurrently deleting Pten exon 5. (b) Multiple-copy transposonbearing (Pten SBm2/+ ; ITP2m; Rosa26 SB11/+ ; Blm m3/m3 -referred to as PISB) mice, which carry Pten SBm2 and a new concatemer with ~35 copies of an inactivating transposon (ITP2m) compatible with the SB and piggyBac (PB) transposases. (c) Tumor incidence in PSB (n = 59: n = 38 male + n = 21 female) and PISB (n = 86: n = 49 male + n = 37 female) mice. Adenoca., adenocarcinoma; PIN, prostatic intraepithelial neoplasia; Hyp., hyperplasia; Pheo., pheochromocytoma; KA, keratoacanthoma; Adenosq. ca., adenosquamous carcinoma; inf., infiltrating. (d) Representative photomicrographs of H&E staining in PSB and PISB tumors (n prostate tumors = 127; n breast tumors = 26; n skin tumors = 125; n pheochromocytomas = 80; n uterine tumors = 50; n intestinal tumors = 36). Scale bars, 200 µm. (e) Kaplan-Meier survival plot of PSB, PISB, ISB and SB mice. PSB versus PISB (P < 0.0001); PSB versus ISB (P < 0.0001); PSB versus SB (P < 0.0001); PISB versus ISB (P < 0.0001); PISB versus SB (P < 0.0001); ISB versus SB (P = 0.0253); by log-rank test. (f) Venn diagram of prostate, breast and skin CIS genes. Top ten most highly mutated genes specific for each tumor type, and seven genes found in all three tumor types, in both the PSB and PISB cohorts are listed. Genes in bold were found in screens for both the PSB and PISB mice.
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A r t i c l e s and Supplementary Table 11 ). Moreover, consideration of only deleted genes in the TCGA database that were also downregulated in prostate cancer led to sharply increased significance of the intersections (P = 0.00088, P = 4.74 × 10 −10 and P = 0.00086, respectively; by Fisher's exact test), further supporting the involvement of these genes as tumor suppressor genes (Supplementary Fig. 4d,e and Supplementary Table 12 ).
General features of PSB and PISB prostate cancer CIS genes
To identify the genes that contributed to prostate cancer progression, we focused on the curated PSB∩PISB hCIS (117 mouse genes corresponding to 115 human orthologs) ( Supplementary Table 13 ). The analysis of their transposon integration pattern (as well as of those of breast and skin tumors) showed the presence of insertions scattered along these genes, consistent with their involvement in tumor suppressor functions (Supplementary Figs. 5-7) . Accordingly, RNA sequencing (RNA-seq) analysis of prostate tumors from PSB and PISB mice identified chimeric transcripts of CIS genes in which transposon insertions caused disruption of their reading frames ( Supplementary Table 14 ).
To demonstrate the significance of these CIS genes, we studied their distribution among the tumors analyzed. As shown in Figure 2e , a number of genes were hit by transposons in most neoplasms (a phenomenon also seen in breast and skin tumors; Supplementary  Fig. 3b,e) , with a median of 20 and 33 hits per prostate tumor in the PSB and PISB cohorts, respectively. The presence of multiple hits per tumor in the single-transposon cohort supports the co-existence of multiple tumor subclones with different insertions that cooperate with Pten disruption within a tumor. This is in line with recent human studies A r t i c l e s that provide evidence for polyclonality in prostate cancer [32] [33] [34] . Genes that were frequently mutated in the tumors from the PSB mice were also highly mutated in the tumors from the PISB cohort (R = 0.82, P < 2.2 × 10 −16 ) ( Fig. 2f) , demonstrating their importance for driving prostate cancer. Significant, positive correlations were also detectable in breast (R = 0.77, P = 1.17 × 10 −4 ) and skin (R = 0.88, P < 2.2 × 10 −16 ) tumors ( Supplementary Fig. 3c,f) .
To explore the potential cooperation of these genes with PTEN inactivation in driving prostate tumorigenesis, we evaluated the mRNA expression levels of PTEN and our list of PSB∩PISB genes in human prostate tumors from the TCGA, Taylor 35 and Barbieri 36 data sets. Of note, the PSB∩PISB hCIS set was highly enriched in genes whose mRNA expression levels correlated with those of PTEN, which might reflect a tendency for PSB∩PISB hCIS genes to be co-regulated with PTEN (Fig. 2g) . This finding suggested the validity of our screen in pinpointing genes that are involved in PTEN-related processes in prostate cancer.
Deregulated pathways in tumors from PSB and PISB mice
To explore the molecular and biological function of the prostate PSB∩PISB CIS genes, we applied DAVID gene set enrichment analysis 37 using Kyoto Encyclopedia of Genes and Genomes (KEGG), BioCarta and Gene Ontology (GO) term data sets ( Fig. 3a and Supplementary Table 15 ) (for similar breast and skin CIS analyses, see Supplementary Tables 16 and 17) . Chromatin-or histonemodifying enzymes constitute one of the most significantly enriched pathways. Histone methylase-encoding genes, such as ARID1A, or those encoding members of the MLL protein family (MLL1 and MLL5) are recurrently mutated in prostate cancer, in association with advanced disease stages 36, 38 . Moreover, MLL1 and MLL5 interact with the androgen receptor (AR), a key player in prostate tumorigenesis 38 . Additionally, loss of the histone acetylase CREBBP cooperates with PTEN haploinsufficiency in driving prostate cancer 39 .
We identified a large number of genes involved in RNA stability, splicing and transcriptional regulation. The homeodomain transcription factors encoded by MEIS1 and PBX1, which are known oncogenes for other malignancies, are downregulated at various stages of prostate cancer progression 40 . Our results constitute the first in vivo indication of their tumor suppressive role in the prostate. In the case of Pbx1, transposon distribution and chimeric transcript data supported this view ( Supplementary Fig. 5 and Supplementary Table 14) . Similarly, the gene encoding the transcription factor FOXP1 has been described as an oncogene or a tumor suppressor, depending on the context 4, 41 . The distribution of insertions along Foxp1 in our screen points to a tumor suppressor role, in agreement with recent findings in human prostate cancer 42 (Supplementary Fig. 5 ). Another notable transcription-factor-encoding gene we found in our screen and that is known to be altered in prostate cancer is ETV6. Unlike other ETSfactor-encoding genes, ETV6 is not involved in gene fusions in human prostate tumors. Instead, ETV6 is hemizygously deleted in ~25% of clinically localized prostate cancer, consistent with our results 43 .
Genes whose products are involved in ubiquitin-mediated proteolysis were also significantly enriched, especially those encoding E3 ubiquitin ligases. Exome sequencing of 112 prostate adenocarcinomas has previously identified SPOP, which encodes the substrate-binding subunit of the CUL3-based E3 ligase, as the gene most frequently mutated in this malignancy 36 . The Cul3 CIS we observed in our screen suggests that alterations in other members of this E3 ligase complex may have similar consequences.
Alterations in intracellular membrane trafficking, intercellular communication or cytoskeleton organization also emerged as important molecular networks that can compromise cell polarity. PTEN has essential roles in cellular polarization, in part by recruitment to the endocytic vesicles 44, 45 . Thus, the PTEN-interacting polarity protein PARD3, a tumor suppressor in different tumor types but unexplored in prostate cancer, emerged as a notable candidate.
Finally, our screens identified alterations of central signaling networks in prostate cancer, such as androgen receptor (AR) signaling (Nrip1, Yy1, Mll1, Mll5 and Foxp1), RAS and mitogen-activated protein kinase (MAPK) signaling (Rasa1, Nf1 and Erbb2ip), and phosphatidylinositol 3-kinase (PI3K)-AKT serine/threonine kinase 1 (AKT) signaling (Pik3r1, Magi3 and Pten-competitive endogenous RNAs (ceRNAs)). In fact, a large number of putative Pten ceRNAs, including the validated ceRNAs Cnot6l and Tnrc6b 20,46 , were present among our CIS. In the polyclonal tumors from PSB and PISB mice, disruption of Pten ceRNAs would further decrease Pten function in those subclones without Pten LOH. In a previous SB screen focusing on melanoma, 33 Pten ceRNAs were identified 20 . We found a significant overlap between these and our CIS genes (PSB, P = 6.58 × 10 −10 ; PISB, P < 2.2 × 10 −16 ; PSB∩PISB, P = 3.63 × 10 −11 ; by Fisher's exact test) ( Supplementary Fig. 8a and Supplementary Table 18 ). Moreover, our CIS genes were significantly enriched among the PTEN ceR-NAs predicted by the ceFINDER algorithm 47 (PSB, P = 4.51 × 10 −12 ; PISB, P < 2.2 × 10 −16 , PSB∩PISB, P = 2.44 × 10 −10 ; by Fisher's exact test) ( Supplementary Fig. 8b and Supplementary Table 19 ).
Co-silencing of PTEN and candidate genes drives invasion
To explore the role of the identified genes in the evolution of cancer, we used small interfering RNAs (siRNAs) to silence the expression of candidate genes in two immortalized but nontransformed human prostate cell lines, named BPH-1 and RWPE-1. In contrast to cancer cells, immortalized cells more closely resemble the primary cells they derive from and, therefore, do not contain cancer-driving genetic alterations. Thus, we tested the effect of inhibiting the expression of our CIS genes, either alone or in combination with PTEN silencing, on their invasive ability in vitro.
We selected five of the twenty genes that were most frequently hit by transposons in our screens, which were not annotated in the Cancer Gene Census and for which a role in prostate cancer had not been described so far ( Fig. 3b and Table 1 ). These genes were ZBTB20 (zinc finger and BTB domain containing 20), CELF2 (CUGBP, Elavlike family member 2), AKAP13 (A-kinase anchor protein 13), PARD3 (Par-3 family cell polarity regulator) and WAC (WW-domain-containing adaptor with coiled coil). Co-silencing the expression of PTEN together with that of each of the candidate genes in BPH-1 and RWPE-1 cells sharply increased the invasiveness of the cell lines ( Fig. 4a, Supplementary Fig. 9 and Supplementary Table 20 ). This synergistic effect is consistent with there being a cooperative role of these genes with PTEN in preventing malignant progression.
Oncogenic pathways disrupted by co-silencing
To examine the molecular basis of this phenotype, we performed RNA-seq transcriptomic profiling of BPH-1 and RWPE-1 cell lines after silencing of the expression of the candidate genes, either alone or with co-silencing of PTEN expression ( Supplementary Fig. 10 and Supplementary Tables 21-25 ). Principal component analysis showed that the first component was determined by the cell line, whereas the second component discriminated single-gene knockdown from co-silencing conditions (Fig. 4b) . This suggested the rewiring of common molecular pathways irrespective of the gene being co-silenced with PTEN.
Pathway enrichment analysis of transcriptional changes associated with co-silencing (versus those associated with PTEN silencing alone), High ZBTB20 Low ZBTB20 A r t i c l e s showed common themes that were shared by the candidates (Fig. 4c  and Supplementary Tables 26-35) . Among the upregulated genes, enrichment was detected for pathways promoting cancer progression: epithelial-mesenchymal transition, MYC-dependent transcriptional activation, MET-RAS-MAPK signaling and PI3K-AKT-MTOR signaling. Accordingly, western blot analysis showed that, as compared to those by PTEN silencing alone, co-silencing of each of the candidates induced increased levels of phosphorylated AKT (p-AKT) and/or p-MTOR, without further reduction of PTEN levels (Supplementary Fig. 11) . The downregulated genes were enriched in pathways including mitotic spindle formation, Rho GTPases, DNA damage response, and transforming growth factor (TGF)-β and AR signaling. PTEN deletion in human and mouse prostate tumors has been previously described to decrease the AR transcriptional output, as the PI3K and AR oncogenic pathways cross-regulate each other by reciprocal feedback 48 . Several of these pathways (AR, RAS-MAPK and PI3K-AKT) were also overrepresented in the PSB∩PISB CIS from prostate tumors.
Clinical relevance of validated genes
We then analyzed the mRNA expression of these genes in prostate tumors from the TCGA data set. ZBTB20, CELF2, PARD3, AKAP13 and WAC mRNA levels were significantly reduced in primary prostate cancer samples (n = 336) compared with benign tissues (n = 65) ( Fig. 5a) .
To investigate more advanced stages of the disease, we analyzed the Taylor data set 35 , which includes primary (n = 131) and metastatic (n = 29) samples. We observed a further reduction of mRNA expression of these genes after progression to metastasis (Fig. 5b) . Additionally, a positive correlation was detected between PTEN and ZBTB20, CELF2, PARD3 or WAC gene expression in primary tumors (Fig. 5c) . This was stronger (and extensive to AKAP13) when more advanced tumors were included in the analysis (Fig. 5d) , supporting the idea of cooperation between PTEN and these genes in preventing cancer progression. With the exception of that for CELF2, the correlation was clearer for log 2 (PTEN expression levels) > 8.5. Although gene-expression-independent regulatory mechanisms might operate, this observation could also reflect that the contribution of ZBTB20, PARD3, AKAP13 and WAC in preventing cancer progression was stronger when PTEN function was perturbed but not lost. In addition to these observations, recurrence-free survival of patients with tumors that expressed low levels of these genes was notably reduced (Fig. 5e ). This was also true for ZBTB20, AKAP13 and WAC when the analysis was restricted to primary tumors (Supplementary Fig. 12) . Taken together, these results highlight the clinical relevance of the PTEN-cooperating tumor suppressor genes we identified.
Wac: a new obligate haploinsufficient prostate cancer gene
To explore the in vivo effects of Wac disruption on prostate tumorigenesis in mice, we generated a mouse model in which there was prostate-specific homozygous inactivation of Pten (Pten ∆/∆ ) combined with prostate-specific heterozygous (Wac +/∆ ) or homozygous (Wac ∆/∆ ) deletion of Wac. Tumor development in these mice disclosed complex interactions between the Wac and Pten deficiencies. Relative to the size of tumors in the prostate-specific Pten ∆/∆ mice, prostatespecific Pten ∆/∆ ; Wac +/∆ mice developed larger tumors, whereas prostate-specific Pten ∆/∆ ; Wac ∆/∆ mice were protected from tumor progression ( Fig. 6a) . This showed a phenomenon of obligate haploinsufficiency, by which, in the presence of a Pten deficiency, partial Wac inactivation potentiated tumor growth, whereas complete Wac inactivation precluded it.
The tumor-promoting effect of partial Wac inactivation was more evident at earlier cancer development stages-it led to significantly increased tumor sizes in 4-month-old Pten ∆/∆ ; Wac +/∆ mice, whereas there was only a tendency toward larger tumors in mice 5 months later (Fig. 6a,b) . This is consistent with the proposed role of Wac as an activator of autophagy, a process known to exert dual effects on cancer, suppressing tumor initiation and promoting the growth of established cancers [49] [50] [51] [52] .
DISCUSSION
PTEN, the second most frequently mutated or deleted gene in human cancer, is a key controller of signaling nodes in multiple tumor types 53, 54 . On the basis of a novel strategy that couples targeted gene inactivation to single-copy transposon mobilization, we performed a genome-wide survey for genes that cooperate with Pten in suppressing tumorigenesis in mice. Our model recapitulated the progressive histological, immunohistochemical and genetic alterations of human prostate cancer, confirming its suitability for the molecular characterization of this malignancy. Our studies identified comprehensive landscapes of tissue-specific and global Ptencollaborating genes, pathways and biological processes, including RNA metabolism, chromatin remodeling or ubiquitin-mediated proteolysis. Previous work has proven the utility of transposonbased somatic mutagenesis to identify and validate candidate cancer genes [4] [5] [6] [7] [8] [10] [11] [12] [13] . Our strategy meets these objectives and opens new applications of somatic transposition by introducing relevant features to the field.
First, the single-copy transposon limits the number of insertions to one per cell, which is aimed at reducing the number of passenger insertions and increasing the specificity of the screen. To our knowledge, this is the first time a single-copy transposon has been shown to generate functionally relevant CIS in a somatic mutagenesis screen. Second, our approach achieves transposon-dependent targeted gene disruption, which favors the identification of insertions that cooperate with the engineered mutation (in our case, Pten inactivation). Transposons have been successfully used previously, together with Cre-dependent activation or inactivation of known oncogenes and tumor suppressors, including Pten 3, 6, 8, [11] [12] [13] . However, using a Cre-inactivated loxP-flanked (floxed) Pten allele does not guarantee perfect coupling of Pten inactivation and transposon mobilization. ; W a c ∆ /∆ Figure 6 In vivo validation of Wac as a new obligate haploinsufficient gene in prostate cancer. (a,b) Comparison of anterior prostate lobe tumor weight in 4-month-old mice (a) and 9-month-old (b) mice of the indicated genotypes. In a, n = 7 for Pten +/+ mice, n = 7 for Pten ∆/∆ mice, n = 9 for Pten ∆/∆ ; Wac +/∆ mice, and n = 8 for Pten ∆/∆ ; Wac ∆/∆ mice. In b, n = 3 for Pten +/+ mice, n = 7 for Pten ∆/∆ , n = 11 for Pten ∆/∆ ; Wac +/∆ mice, and n = 7 for Pten ∆/∆ ; Wac ∆/∆ mice. In the box plots, boxes display the 25th to 75th percentiles, lines represent the medians, and the whiskers represent the 5th to 95th percentiles. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 by two-tailed Student's t-test.
Representative pictures of tumors (indicated by arrows) from 4-month-old mice are shown for each genotype in a. Scale bars, 50 mm.
In our model, by contrast, transposition happens only in cells that have undergone Pten inactivation, avoiding the development of transposon-induced tumors with intact Pten. Third, our screen exclusively involves inactivating transposition. Although this precludes the identification of potential oncogenes, it facilitates interpretation of the roles of uncharacterized candidate genes. Detailed analysis of prostate cancer CIS showed enrichment in known (CGC) and putative (NCG) cancer genes. All of the genes had insertions that were evenly distributed along their loci, which is the pattern expected for tumor suppressors. Consistently, they overlapped significantly with genes that show, concurrently, homozygous deletions and downregulation of their expression in TCGA human prostate cancer samples. In addition, they were enriched in genes whose expression levels positively correlated with those of PTEN in human prostate cancer, supporting the specificity of the screen in the identification of PTEN-cooperating genes. We prioritized our characterization and validation efforts on five of the genes that ranked among the 20 most frequently hit prostate cancer CIS and that were not previously described as cancer drivers. We confirmed the effect of genetically inhibiting ZBTB20, CELF2, PARD3, AKAP13 and WAC expression in PTEN-deficient contexts for the enhancement of invasion and the unleashing of canonical cancer-promoting pathways, and we provided evidence of their clinical relevance in human prostate cancer. Finally, we characterized Wac as a new obligate haploinsufficient tumor suppressor in vivo.
The obligate haploinsufficiency of Wac agrees with its proposed role as an autophagy activator 50, 51 . Co-silencing of WAC and PTEN resulted in the downregulation of pathways directly related to autophagy, such as KEGG_LYSOSOME and KEGG_PEROXISOME (false discovery rate (FDR) q-values = 0.000) ( Supplementary Table 35 ). Heterozygous disruption of Becn1, a gene encoding a Wac-interacting protein essential for autophagy, increases the frequency of spontaneous malignancies and accelerates hepatitis B virus (HBV)-induced hepatocellular carcinogenesis 55 . However, liver tumors arising from Becn1 allelic loss do not undergo LOH, suggesting obligate haploinsufficiency 49 . In addition, autophagy abrogation by complete loss of Atg7 delays progression of Pten-deficient prostate tumors 56 . Our results parallel these observations, as heterozygous Wac deletion promoted prostate tumor progression, whereas its complete loss constrained it. Autophagy exerts dual effects on cancer, suppressing initiation but promoting growth of established cancers 49, 52 . Accordingly, Wac inactivation led to significantly larger tumors in 4-month-old Pten ∆/∆ ; Wac +/∆ mice but only a tendency for lesions with increased size was observed 5 months later (Fig. 6a,b) . These findings, which are likely to underlie the modest decrease of WAC mRNA levels that accompanies human prostate cancer progression, are relevant for basic and translational oncology. Moreover, the dependence of Pten-deficient tumors on Wac function opens up potential opportunities for drug development.
Our approach recapitulates the sporadic nature of human tumorigenesis, in which mutations in relevant cancer genes occur randomly in individual cells from any tissue surrounded by healthy cells. Beyond prostate cancer, mice in our cohorts developed several tumor types for which Pten relevance is well documented. Exploration of the potential of the novel putative tumor suppressors in preventing such cancers is warranted. Hopefully, our results will provide a basis for the development of therapeutic strategies inspired by the tumor suppressor networks identified through this screen.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
